Tarsus Pharmaceuticals (TARS) director details options, RSUs and trust shares
Rhea-AI Filing Summary
Tarsus Pharmaceuticals director David E. I. Pyott filed an initial statement of beneficial ownership, reporting his equity holdings in the company. The filing lists several stock options granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan that vested and became exercisable on April 24, 2023, August 1, 2024, and April 24, 2025. Another option grant is scheduled to vest and become exercisable on April 24, 2026, subject to his continuous service. He also holds restricted stock units that vest on April 24, 2026, subject to continuous service. In addition, 7,991 shares of common stock are reported as held indirectly by the David E.I. Pyott Trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
PYOTT DAVID E I
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 14,128 shares (Direct);
Restricted Stock Units — 1,383 shares (Direct);
Common Stock — 7,991 shares (Indirect, By the David E.I. Pyott Trust)
Footnotes (5)
- F1. Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan (the "Plan"). The option shares vested and became exercisable on April 24, 2023.
- F2. Option granted under the Plan. The option shares vested and became exercisable on August 1, 2024.
- F3. Option granted under the Plan. The option shares vested and became exercisable on April 24, 2025.
- F4. Option granted under the Plan. The option shares vest and become exercisable on April 24, 2026, subject to the Reporting Person's continuous service.
- F5. Restricted Stock Units ("RSUs") granted under the Plan. The RSUs vest on April 24, 2026, subject to the Reporting Person's continuous service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does David E. I. Pyott’s Form 3 disclose for Tarsus (TARS)?
The Form 3 discloses David E. I. Pyott’s initial equity holdings in Tarsus Pharmaceuticals, including stock options, restricted stock units, and common shares held indirectly through the David E.I. Pyott Trust as of the reported date.
What stock options does David E. I. Pyott report in his Tarsus (TARS) Form 3?
He reports several stock option awards under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan, with option shares that vested on April 24, 2023, August 1, 2024, and April 24, 2025, plus an additional option scheduled to vest on April 24, 2026.
When do David E. I. Pyott’s restricted stock units in Tarsus (TARS) vest?
The restricted stock units reported in the Form 3 were granted under the Tarsus 2020 Stock Plan and are scheduled to vest on April 24, 2026, provided that David E. I. Pyott maintains continuous service with the company through that date.
Does this Tarsus (TARS) Form 3 show any insider stock purchases or sales?
No, the Form 3 does not show any insider purchases or sales. It is an initial statement of beneficial ownership listing existing holdings, with all transactions categorized as holdings and no buy or sell transactions reported.
What role does David E. I. Pyott hold at Tarsus (TARS) according to the Form 3?
According to the filing, David E. I. Pyott is a director of Tarsus Pharmaceuticals. The Form 3 outlines his beneficial ownership in company equity, including options, restricted stock units, and indirectly held common shares through a trust.